By interrogating host-virus interactions with a transcriptome analysis with various cancers, Chakravorty et al. (2019) found that the interferon (IFN)-activation status signature discriminates the EBV-associated diseases as IFN-activated (IFN+) cancers, such as GaC, and NPC; and IFN-inhibited (IFN−) cancers, comprising BL (either endemic or sporadic), angioimmunoblastic T-cell lymphoma (AITL), and NKTCL. This evidence concerns the gene IFNA1 and Burkitt lymphoma.